Sensus Healthcare (NASDAQ:SRTS) versus Artivion (NYSE:AORT) Head-To-Head Contrast

Sensus Healthcare (NASDAQ:SRTSGet Free Report) and Artivion (NYSE:AORTGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Institutional and Insider Ownership

20.6% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 83.3% of Artivion shares are owned by institutional investors. 11.1% of Sensus Healthcare shares are owned by insiders. Comparatively, 6.6% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Sensus Healthcare and Artivion’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sensus Healthcare $24.41 million 2.82 $490,000.00 $0.03 140.05
Artivion $313.79 million 2.30 -$19.19 million ($0.60) -29.32

Sensus Healthcare has higher earnings, but lower revenue than Artivion. Artivion is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Sensus Healthcare and Artivion, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensus Healthcare 0 0 1 0 3.00
Artivion 0 0 1 0 3.00

Sensus Healthcare currently has a consensus target price of $7.50, indicating a potential upside of 78.57%. Artivion has a consensus target price of $22.00, indicating a potential upside of 25.07%. Given Sensus Healthcare’s higher probable upside, research analysts plainly believe Sensus Healthcare is more favorable than Artivion.

Risk and Volatility

Sensus Healthcare has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Profitability

This table compares Sensus Healthcare and Artivion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sensus Healthcare 1.99% 1.06% 0.93%
Artivion -7.23% 2.88% 1.05%

Summary

Sensus Healthcare beats Artivion on 7 of the 12 factors compared between the two stocks.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and TransDermal Infusion system. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body, as well as distributes laser devices. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

About Artivion

(Get Free Report)

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.